Eszak-Budai Szent Janos Centrumkorhaz — Clinical Trial Site

17 Registered trials

7 Currently recruiting

Organisation

Eszak-Budai Szent Janos Centrumkorhaz

Location

Budapest XII, Hungary

Identifier

ORG-100045829

Address

Kutvolgyi Ut 4, 1125, Hungary

Departments

Budai Gyermekkórház Telephely, Epilepszianeurológiai Szakambulancia
Budai Családközpontú Lelki Egészség Centrum
Emergency Medicine
Epilepszia-Neurológia Szakambulancia
Észak-Közép-budai Centrum, Szent János Kórház és Szakrendel
Gyermek-, Koraszülött és Csecsemőosztály
I. Belgyógyászat – Gasztroenterológiai Osztály
I. Belgyogyaszat, Gasztroenterologia
II. Belgyógyászat
N/A
Neurológiai Osztály
Neurológiai Osztály - Stroke Centrum
Neurológiai osztály – stroke centrum
Neurology Department
PICU, Saint John's Cnetral Hospital Busapest
Urológiai-Sebészeti Osztály

Clinical trials at this site (17)

Search interface

A Study to Learn About the Study Medicine Called Aztreonam-Avibactam in Neonates and Infants Less Than 9 Months of Age With Suspected or Con… Pending

2023-507757-15-01 Blood Stream Infection 4
A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending

2023-509176-42-00 Obesity and T2D 11
Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o… Pending

2025-521632-12-00 Patients on Factor Xa inhibitor treatment needing an ur 5
A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting

2024-513911-28-00 Acute Ischemic Stroke 10 2026-03-04
Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting

2024-517032-22-00 Immune system diseases. 5 2025-06-10
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease Recruiting

2024-516363-92-00 Psychosis Associated with Alzheimer’s Disease 5 2025-04-08
The effect of additional pre-extubational loading dose of caffeine-citrate Recruiting

2024-519041-29-02 Extubation failure and bronchopulmonary dysplasia 6 2025-01-15
A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron… Recruiting

2023-508338-33-00 Chronic Inflammatory Demyelinating Polyneuropathy 5 2024-10-01
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting

2023-504151-27-00 Psychosis associated with Alzheimer’s Disease 5 2024-05-09
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
"Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures " Ended

2023-506841-52-00 partial-onset (focal) seizures 5 2023-03-22
Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended

2023-505852-23-00 High risk recurrent prostate cancer previously treated 5 2020-11-12
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14
Open-label extesnion study of soticlestat in Dravet and Lennox-Gastaut Syndromes Ended

2022-502802-34-00 Dravet and Lennox-Gastaut Syndromes 5 2022-04-05
A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended

2024-513304-33-00 Type 1 diabetes mellitus 5 2022-03-17